Legend Biotech (LEGN) Stock: CARVYKTI Revenue Soars 66% in Q4 with 2026 Profit Target
Legend Biotech (LEGN) stock analysis: CARVYKTI Q4 sales surge 66% to $555M, manufacturing scales up, and company targets enterprise profitability by 2026. The post
2026/03/10